Latest Paul Noble Stories
Idiopathic pulmonary fibrosis (IPF) affects about 100,000 people in the US each year and is fatal within three years of diagnosis.
An invasive cell that leads to fibrosis of the lungs may be stopped by cutting off its supply of sugar.
- Results suggest pirfenidone may provide meaningful clinical benefit in IPF patients - - Results of new analyses of efficacy and safety reported - - Conference Call and Webcast at 9 p.m. EDT (6 p.m. PDT) - SAN DIEGO, May 19 /PRNewswire-FirstCall/ -- InterMune, Inc.
- Emitting flashes of light; glittering.